CARYSIL
German Engineered

STERNHAGEN
GERMANY

February 08, 2021

To,
BSE Limited
Department of Corporate Services
Phiroze Jeejeebhoy Towers,
Dalal Street,
Mumbai- 400 001
Scrip Code: 524091

To,
National Stock Exchange of India Limited
Exchange Plaza, Plot No. C/1
'G' Block, Bandra – Kurla Complex
Bandra East,
Mumbai 400 051
Trading Symbol: ACRYSIL

Dear Sir/Madam,

Sub: Submission of Newspaper Clipping of Extract of Un-audited Financial Results (Standalone & Consolidated) for the Quarter and nine months ended on December 31, 2020

This is to inform you that in compliance with Regulation 30 & 47 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, we are enclosing herewith the copies of Newspaper Clippings of the publication of the Extracts of the Un-audited Financial Results (Standalone and Consolidated) for the Quarter and nine months ended on December 31, 2020 published in Business Standard – All Editions and Mumbai Lakshadeep (with Marathi Translation) on February 06, 2021 and in The Economic Times – Mumbai on February 08, 2021,

Please take the same on record.

Thanking you,

Yours faithfully,
For **ACRYSIL LIMITED**

Neha

NEHA PODDAR
COMPANY SECRETARY

ACRYSIL LIMITED MUMBAI

Encl.: a/a

More vaccine candidates get nod for clinical trials

SOHINI DAS
Mumbai, 5 February

A bunch of Covid-19 vaccine candidates got approval from the expert panel to conduct clinical trials in India, including one from Novavax, Bharat Biotech's intra-nasal candidate, and a measles vector-based candidate from Zydus Cadila.

In its February 3 meeting, the subject expert panel (SEC) advising the Central Drugs Standard Control Organisation (CDSCO) recommended that approval be granted for conducting phase II/III clinical trials to Serum Institute of India (SII) for the Novavax candidate. This vaccine is based on protein nanoparticle and uses the proprietary Matrix-M adjuvant from Novavax. Adjuvants are pharmacological or immunological agents that improve the immune response of a vaccine.

The SEC has noted that participants randomised in the placebo arm may be un-blinded 60 days after the second dose, upon request from the clinical trial participant only. Blinded vaccine trials are those where the participant, investigator and sponsor do not know whether a person was given a vaccine or a placebo.

Trials will be held for vaccine candidate from Novavax, Bharat Biotech's intra-nasal candidate, and a measles vector-based candidate from Zydus

As for Bharat Biotech's chimpanzee flu virus (adenovirus) based intra-nasal vaccine candidate, the SEC recommended grant of permission for phase I trials.

Ahmedabad-based Zydus Cadila got approval for conducting phase I/II trials for the 2019-nCoV vaccine 3mg (two dose schedule). The SEC has noted that safety should be the primary objective of the study.

This is Zydus Cadila's second vaccine candidate, developed by its European research arm Etna Biotech. It is a live weakened recombinant measles virus vector-based vaccine against Covid-19. The genetically engineered measles virus vector would express proteins of the novel coronavirus and, thus, induce long-term specific neutralising antibodies.

Meanwhile, Aurobindo Pharmaceuticals has been asked to submit a revised clinical trial protocol for its vaccine candidate UB-612. The firm presented animal study and phase I data before the committee. The SEC recommended that Aurobindo submit the phase II/III clinical trial protocols approved by the regulatory authority of Brazil and some other conditions.

API sales momentum begins to normalise

SOHINI DAS & VINAY UMARJI
Mumbai/Ahmedabad, 5 February

After witnessing a momentum in active pharmaceutical ingredients (API) sales on account of formulation/medicine makers stocking up during the pandemic, drug makers have begun to see some correction on a sequential basis.

With API supply, especially from China, facing some constraints because of lockdowns in several countries, demand from global clients had shot up for Indian players. This had led to a spurt in API sales in the first two quarters of FY21.

However, with global clients now having adequate inventory, the order growth is beginning to normalise or slowdown in certain cases. This is evident from the Q3 results of several pharma firms that show a sequential dip or muted growth in API sales after picking up significantly in the first half of the year.

For example, a leading API player — Dr Reddy's Laboratories (DRL) — has seen an 18 per cent drop in revenues from pharmaceutical services and active ingredients on a sequential basis in Q3, while on a year-on-year (YoY) basis the rise is 1 per cent. Erez Israeli, chief executive of DRL, said: "There has been an inventory accumulation by our customers in the first two quarters. Thus, there has been a dip now (in terms of demand). We are looking for more markets."

Mumbai-headquartered Cipla has managed to post growth sequentially, but the rate of growth has slumped. While on YoY basis, the API revenue grew 22 per cent, on quarter-on quarter (QoQ) it grew 7 per cent in Q3FY21.

Kedar Upadhye, global chief financial officer, Cipla, said the industry was stocking up APIs in the first half of FY21. "Part of this was due to Wuhan crisis and API shortage, while partly formulation players wanted to stock up APIs to avoid production disruption. We also stocked up. So, going forward the uptake of APIs will slow down a bit," he explained.

Lupin, too, has seen a dip in API sales on a sequential basis, around 8.1 per cent decline in Q3FY21 compared to the previous quarter. On YoY basis, however, it has grown 8.4 per cent. "There was a momentum in pharma industry in the first half of the financial year and global demand for APIs shot up. However, we will see that correction happening across the stocks as API demand is fizzling out. So, the results for API will be subdued in the second half against the first half," an analyst said.

Sun Pharma, on the other hand, saw its external sales of API fall by 10.5 per cent to ₹450 crore in the third quarter of FY21 on YoY basis over Q3 last year. For nine months, API sales of Sun Pharma were at ₹1,515 crore, up 5.7 per cent. However, the company said its API business imparted benefits of vertical integration and continuity of supply chain for its formulations business. "We continue to focus on increasing API supply for captive consumption for key products," the company said.

Alembic Pharmaceuticals' API business grew nearly 21 per cent YoY to ₹210 crore. According to experts, the demand opportunities are set to reduce.

"Demand opportunities have started to reduce, with supplies resuming from China. It is incrementally adding capacities to de-bottleneck its plants. The temporary spurt in prices seemed to have normalised," ICICI Securities said in its note on Alembic Pharma.

Biocon's generics business revenue was down 3 per cent to ₹561 crore, as its portfolio of statin APIs were impacted because of muted demand.

Domestic drug market growth slows to 4.5% in January



After a robust performance in December, the domestic pharma market crawled back to a slower growth trend in January. Dragged by some therapy areas, the Indian Pharmaceutical Market (IPM) grew 4.5 per cent in January against an 8.5 per cent growth in December.

Cardiac therapy registered monthly growth of 8.8 per cent in January against 14.9 per cent in December, showed the data from market research firm AIOCD AWACS. Anti-diabetic, on the other hand, grew 5.3 per cent in January against 9.9 per cent growth in December. Among firms, Sun Pharmaceuticals grew 5.1 per cent while Lupin posted 4.6 per cent growth. Mankind did well at 9.3 per cent while Cipla growth came in at 4.2 per cent. SOHINI DAS

Zydus Cadila's net profit up 41% on India biz growth

VINAY UMARJI
Ahmedabad, 5 February

Led by a double-digit growth in its India business, Cadila Healthcare (Zydus Cadila) has reported 41 per cent increase in its consolidated net profit at ₹527.2 crore in the third quarter. The Ahmedabad-based drug maker's consolidated net profit was ₹373.9 crore in the year-ago period.

Its consolidated revenue from operations grew by 6.20 per cent in the third quarter to ₹3,753.7 crore against ₹3,534.5 crore in the same period in 2019-20.

The company's business in India comprising human health formulations, consumer wellness, and animal health increased 20 per cent year-on-year (YoY) during the quarter at ₹1,643 crore. Of these, while human health formulations business in India contributed 21 per cent to the company's growth, consumer wellness and animal health businesses grew 16 per cent and 17 per cent YoY, respectively.

However, Zydus Cadila's US formulations business declined 4 per cent YoY in the quarter with revenues of ₹1,603 crore against ₹1,675 crore in the year-ago quarter.

The third quarter saw Zydus file 10 additional abbreviated new drug applications with the US Food and Drug Administration taking the cumulative number of filings to 410. During the quarter, the firm launched the oral anti-diabetic agent, Dapaglyn in India for patients suffering from chronic obstructive pulmonary disorder.

Sales of Ivermectin, drug to treat parasitic infections, jump fourfold

SOHINI DAS & RUCHIKA CHITRAVANSHI
Mumbai/New Delhi, 5 February

Ivermectin, a drug used to treat parasitic infections, rose to prominence in 2020 as a treatment for Covid-19, pushing its sales up by more than 25 times, prompting more drug firms to launch the product.

Though demand for Ivermectin slowed with the rise of antivirals like remdesivir and favipiravir, experts feel its relevance as a prophylaxis remains. Annual sales of Ivermectin were around ₹19 crore in 2018 and went up to ₹21 crore in 2019. In 2020 it shot up to ₹94 crore. The drug's sales grew from ₹1.7 crore in April to ₹26.8 crore in September, riding on Covid-19 demand, shows data from market research firm AIOCD AWACS.

Mumbai-based pulmonologist Dr Agam Vora said in the first few months of the pandemic, the line of treatment was not established. "Ivermectin emerged as one of the better options around at the time as it has hardly any side effects and has no drug-to-drug interaction. It is inexpensive and easily available. The best part is its prophylactic properties," Dr Vora said. He has published papers on the role of Ivermectin in treating mild cases of Covid-19.

Dr Vora said by the time Ivermectin popularity grew, antivirals like favipiravir and remdesivir came along. This hit demand for the drug, which saw sales dip to ₹8.6 crore in December.



BOOSTER DOSE

Sales value (₹ crore)



Source: AIOCD AWACS

Several firms launched the drug last year, including Mumbai-based JB Chemicals. Nikhil Chopra, chief executive officer of JB Chemicals, said they launched the drug in November. It also launched favipiravir and Chopra feels Ivermectin has not lost its relevance as it has prophylactic properties.

Dr Vora said, "The vaccine would take some time to cover a sizeable population. Until then, safe drugs like Ivermectin can be used as prophylactic to stop the spread of infection."

Firms like Cipla, Sun Pharmaceuticals, Zuventus have popular Ivermectin brands in the market. Kedar Upadhye, global CFO of Cipla, too, said Ivermectin was considered good for Covid-19 before other molecules came along. Sales of the drug first picked up in states like Uttar Pradesh, West Bengal, and it still seems to be doing well in the North.

"We are giving Ivermectin to those who are getting admitted in the hospitals with Covid as well as family members and contacts of the patient... This is in the government protocol," said Subodh Kumar Adarsh, chief medical officer, Agra.

A chief medical officer in Aligarh said the drug, unlike HCQ, which was also a part of the protocol, does not have any major side effects and is easier to use. Medical professionals believe the repurposed drug controls the replication of the virus in the body. However, it works for mild cases and doesn't prevent deaths, a Delhi-based doctor said.

More vaccine candidates get nod for clinical trials

SOHINI DAS
Mumbai, 5 February

A bunch of Covid-19 vaccine candidates got approval from the expert panel to conduct clinical trials in India, including one from Novavax, Bharat Biotech's intra-nasal candidate, and a measles vector-based candidate from Zydus Cadila.

In its February 3 meeting, the subject expert panel (SEC) advising the Central Drugs Standard Control Organisation (CDSCO) recommended that approval be granted for conducting phase II/III clinical trials to Serum Institute of India (SII) for the Novavax candidate. This vaccine is based on protein nanoparticle and uses the proprietary Matrix-M adjuvant from Novavax. Adjuvants are pharmacological or immunological agents that improve the immune response of a vaccine.

The SEC has noted that participants randomised in the placebo arm may be un-blinded 60 days after the second dose, upon request from the clinical trial participant only. Blinded vaccine trials are those where the participant, investigator and sponsor do not know whether a person was given a vaccine or a placebo.

Trials will be held for vaccine candidate from Novavax, Bharat Biotech's intra-nasal candidate, and a measles vector-based candidate from Zydus

As for Bharat Biotech's chimpanzee flu virus (adenovirus) based intra-nasal vaccine candidate, the SEC recommended grant of permission for phase I trials.

Ahmedabad-based Zydus Cadila got approval for conducting phase I/II trials for the 2019-nCoV vaccine 3mg (two dose schedule). The SEC has noted that safety should be the primary objective of the study.

This is Zydus Cadila's second vaccine candidate, developed by its European research arm Etna Biotech. It is a live weakened recombinant measles virus vector-based vaccine against Covid-19. The genetically engineered measles virus vector would express proteins of the novel coronavirus and, thus, induce long-term specific neutralising antibodies.

Meanwhile, Aurobindo Pharmaceuticals has been asked to submit a revised clinical trial protocol for its vaccine candidate UB-612. The firm presented animal study and phase I data before the committee. The SEC recommended that Aurobindo submit the phase II/III clinical trial protocols approved by the regulatory authority of Brazil and some other conditions.

API sales momentum begins to normalise

SOHINI DAS & VINAY UMARJI
Mumbai/Ahmedabad, 5 February

After witnessing a momentum in active pharmaceutical ingredients (API) sales on account of formulation/medicine makers stocking up during the pandemic, drug makers have begun to see some correction on a sequential basis.

With API supply, especially from China, facing some constraints because of lockdowns in several countries, demand from global clients had shot up for Indian players. This had led to a spurt in API sales in the first two quarters of FY21.

However, with global clients now having adequate inventory, the order growth is beginning to normalise or slowdown in certain cases. This is evident from the Q3 results of several pharma firms that show a sequential dip or muted growth in API sales after picking up significantly in the first half of the year.

For example, a leading API player — Dr Reddy's Laboratories (DRL) — has seen an 18 per cent drop in revenues from pharmaceutical services and active ingredients on a sequential basis in Q3, while on a year-on-year (YoY) basis the rise is 1 per cent. Erez Israeli, chief executive of DRL, said: "There has been an inventory accumulation by our customers in the first two quarters. Thus, there has been a dip now (in terms of demand). We are looking for more markets."

Mumbai-headquartered Cipla has managed to post growth sequentially, but the rate of growth has slumped. While on YoY basis, the API revenue grew 22 per cent, on quarter-on quarter (QoQ) it grew 7 per cent in Q3FY21.

Kedar Upadhye, global chief financial officer, Cipla, said the industry was stocking up APIs in the first half of FY21. "Part of this was due to Wuhan crisis and API shortage, while partly formulation players wanted to stock up APIs to avoid production disruption. We also stocked up. So, going forward the uptake of APIs will slow down a bit," he explained.

Lupin, too, has seen a dip in API sales on a sequential basis, around 8.1 per cent decline in Q3FY21 compared to the previous quarter. On YoY basis, however, it has grown 8.4 per cent. "There was a momentum in pharma industry in the first half of the financial year and global demand for APIs shot up. However, we will see that correction happening across the stocks as API demand is fizzling out. So, the results for API will be subdued in the second half against the first half," an analyst said.

Sun Pharma, on the other hand, saw its external sales of API fall by 10.5 per cent to ₹450 crore in the third quarter of FY21 on YoY basis over Q3 last year. For nine months, API sales of Sun Pharma were at ₹1,515 crore, up 5.7 per cent. However, the company said its API business imparted benefits of vertical integration and continuity of supply chain for its formulations business. "We continue to focus on increasing API supply for captive consumption for key products," the company said.

Alembic Pharmaceuticals' API business grew nearly 21 per cent YoY to ₹210 crore. According to experts, the demand opportunities are set to reduce.

"Demand opportunities have started to reduce, with supplies resuming from China. It is incrementally adding capacities to de-bottleneck its plants. The temporary spurt in prices seemed to have normalised," ICICI Securities said in its note on Alembic Pharma.

Biocon's generics business revenue was down 3 per cent to ₹561 crore, as its portfolio of statin APIs were impacted because of muted demand.

Domestic drug market growth slows to 4.5% in January

After a robust performance in December, the domestic pharma market crawled back to a slower growth trend in January. Dragged by some therapy areas, the Indian Pharmaceutical Market (IPM) grew 4.5 per cent in January against an 8.5 per cent growth in December.

Cardiac therapy registered monthly growth of 8.8 per cent in January against 14.9 per cent in December, showed the data from market research firm AIOCD AWACS. Anti-diabetic, on the other hand, grew 5.3 per cent in January against 9.9 per cent growth in December. Among firms, Sun Pharmaceuticals grew 5.1 per cent while Lupin posted 4.6 per cent growth. Mankind did well at 9.3 per cent while Cipla growth came in at 4.2 per cent. SOHINI DAS

Zydus Cadila's net profit up 41% on India biz growth

VINAY UMARJI
Ahmedabad, 5 February

Led by a double-digit growth in its India business, Cadila Healthcare (Zydus Cadila) has reported 41 per cent increase in its consolidated net profit at ₹527.2 crore in the third quarter. The Ahmedabad-based drug maker's consolidated net profit was ₹373.9 crore in the year-ago period.

Its consolidated revenue from operations grew by 6.20 per cent in the third quarter to ₹3,753.7 crore against ₹3,534.5 crore in the same period in 2019-20.

The company's business in India comprising human health formulations, consumer wellness, and animal health increased 20 per cent year-on-year (YoY) during the quarter at ₹1,643 crore. Of these, while human health formulations business in India contributed 21 per cent to the company's growth, consumer wellness and animal health businesses grew 16 per cent and 17 per cent YoY, respectively.

However, Zydus Cadila's US formulations business declined 4 per cent YoY in the quarter with revenues of ₹1,603 crore against ₹1,675 crore in the year-ago quarter.

The third quarter saw Zydus file 10 additional abbreviated new drug applications with the US Food and Drug Administration taking the cumulative number of filings to 410. During the quarter, the firm launched the oral anti-diabetic agent, Dapaglyn in India for patients suffering from chronic obstructive pulmonary disorder.

Sales of Ivermectin, drug to treat parasitic infections, jump fourfold

SOHINI DAS & RUCHIKA CHITRAVANSHI
Mumbai/New Delhi, 5 February

Ivermectin, a drug used to treat parasitic infections, rose to prominence in 2020 as a treatment for Covid-19, pushing its sales up by more than 25 times, prompting more drug firms to launch the product.

Though demand for Ivermectin slowed with the rise of antivirals like remdesivir and favipiravir, experts feel its relevance as a prophylaxis remains. Annual sales of Ivermectin were around ₹19 crore in 2018 and went up to ₹21 crore in 2019. In 2020 it shot up to ₹94 crore. The drug's sales grew from ₹1.7 crore in April to ₹26.8 crore in September, riding on Covid-19 demand, shows data from market research firm AIOCD AWACS.

Mumbai-based pulmonologist Dr Agam Vora said in the first few months of the pandemic, the line of treatment was not established. "Ivermectin emerged as one of the better options around at the time as it has hardly any side effects and has no drug-to-drug interaction. It is inexpensive and easily available. The best part is its prophylactic properties," Dr Vora said. He has published papers on the role of Ivermectin in treating mild cases of Covid-19.

Dr Vora said by the time Ivermectin popularity grew, antivirals like favipiravir and remdesivir came along. This hit demand for the drug, which saw sales dip to ₹8.6 crore in December.

BOOSTER DOSE

Sales value (₹ crore)



Source: AIOCD AWACS

Several firms launched the drug last year, including Mumbai-based JB Chemicals. Nikhil Chopra, chief executive officer of JB Chemicals, said they launched the drug in November. It also launched favipiravir and Chopra feels Ivermectin has not lost its relevance as it has prophylactic properties.

Dr Vora said, "The vaccine would take some time to cover a sizeable population. Until then, safe drugs like Ivermectin can be used as prophylactic to stop the spread of infection."

Firms like Cipla, Sun Pharmaceuticals, Zuventus have popular Ivermectin brands in the market. Kedar Upadhye, global CFO of Cipla, too, said Ivermectin was considered good for Covid-19 before other molecules came along. Sales of the drug first picked up in states like Uttar Pradesh, West Bengal, and it still seems to be doing well in the North.

"We are giving Ivermectin to those who are getting admitted in the hospitals with Covid as well as family members and contacts of the patient... This is in the government protocol," said Subodh Kumar Adarsh, chief medical officer, Agra.

A chief medical officer in Aligarh said the drug, unlike HCQ, which was also a part of the protocol, does not have any major side effects and is easier to use. Medical professionals believe the repurposed drug controls the replication of the virus in the body. However, it works for mild cases and doesn't prevent deaths, a Delhi-based doctor said.

More vaccine candidates get nod for clinical trials

SOHINI DAS
Mumbai, 5 February

A bunch of Covid-19 vaccine candidates got approval from the expert panel to conduct clinical trials in India, including one from Novavax, Bharat Biotech's intra-nasal candidate, and a measles vector-based candidate from Zydus Cadila.

In its February 3 meeting, the subject expert panel (SEC) advising the Central Drugs Standard Control Organisation (CDSCO) recommended that approval be granted for conducting phase II/III clinical trials to Serum Institute of India (SII) for the Novavax candidate. This vaccine is based on protein nanoparticle and uses the proprietary Matrix-M adjuvant from Novavax. Adjuvants are pharmacological or immunological agents that improve the immune response of a vaccine.

The SEC has noted that participants randomised in the placebo arm may be un-blinded 60 days after the second dose, upon request from the clinical trial participant only. Blinded vaccine trials are those where the participant, investigator and sponsor do not know whether a person was given a vaccine or a placebo.


Trials will be held for vaccine candidate from Novavax, Bharat Biotech's intra-nasal candidate, and a measles vector-based candidate from Zydus

As for Bharat Biotech's chimpanzee flu virus (adenovirus) based intra-nasal vaccine candidate, the SEC recommended grant of permission for phase I trials.

Ahmedabad-based Zydus Cadila got approval for conducting phase I/II trials for the 2019-nCoV vaccine 3mg (two dose schedule). The SEC has noted that safety should be the primary objective of the study.

This is Zydus Cadila's second vaccine candidate, developed by its European research arm Etna Biotech. It is a live weakened recombinant measles virus vector-based vaccine against Covid-19. The genetically engineered measles virus vector would express proteins of the novel coronavirus and, thus, induce long-term specific neutralising antibodies.

Meanwhile, Aurobindo Pharmaceuticals has been asked to submit a revised clinical trial protocol for its vaccine candidate UB-612. The firm presented animal study and phase I data before the committee. The SEC recommended that Aurobindo submit the phase II/III clinical trial protocols approved by the regulatory authority of Brazil and some other conditions.

API sales momentum begins to normalise

SOHINI DAS & VINAY UMARJI
Mumbai/Ahmedabad, 5 February

Domestic drug market growth slows to 4.5% in January

After a robust performance in December, the domestic pharma market crawled back to a slower growth trend in January. Dragged by some therapy areas, the Indian Pharmaceutical Market (IPM) grew 4.5 per cent in January against an 8.5 per cent growth in December.

Cardiac therapy registered monthly growth of 8.8 per cent in January against 14.9 per cent in December, showed the data from market research firm AIOCD AWACS. Anti-diabetic, on the other hand, grew 5.3 per cent in January against 9.9 per cent growth in December. Among firms, Sun Pharmaceuticals grew 5.1 per cent while Lupin posted 4.6 per cent growth. Mankind did well at 9.3 per cent while Cipla growth came in at 4.2 per cent. SOHINI DAS

After witnessing a momentum in active pharmaceutical ingredients (API) sales on account of formulation/medicine makers stocking up during the pandemic, drug makers have begun to see some correction on a sequential basis. With API supply, especially from China, facing some constraints because of lockdowns in several countries, demand from global clients had shot up for Indian players. This had led to a spurt in API sales in the first two quarters of FY21.

However, with global clients now having adequate inventory, the order growth is beginning to normalise or slowdown in certain cases. This is evident from the Q3 results of several pharma firms that show a sequential dip or muted growth in API sales after picking up significantly in the first half of the year.

For example, a leading API player — Dr Reddy's Laboratories (DRL) — has seen an 18 per cent drop in revenues from pharmaceutical services and active ingredients on a sequential basis in Q3, while on a year-on-year (YoY) basis the rise is 1 per cent. Erez Israeli, chief executive of DRL, said: "There has been an inventory accumulation by our customers in the first two quarters. Thus, there has been a dip now (in terms of demand). We are looking for more markets."

Mumbai-headquartered Cipla has managed to post growth sequentially, but the rate of growth has slumped. While on YoY basis, the API revenue grew 22 per cent, on quarter-on quarter (QoQ) it grew 7 per cent in Q3FY21.

Kedar Upadhye, global chief financial officer, Cipla, said the industry was stocking up APIs in the first half of FY21. "Part of this was due to Wuhan crisis and API shortage, while partly formulation players wanted to stock up APIs to avoid production disruption. We also stocked up. So, going forward the uptake of APIs will slow down a bit," he explained.

Lupin, too, has seen a dip in API sales on a sequential basis, around 8.1 per cent decline in Q3FY21 compared to the previous quarter. On YoY basis, however, it has grown 8.4 per cent. "There was a momentum in pharma industry in the first half of the financial year and global demand for APIs shot up. However, we will see that correction happening across the stocks as API demand is fizzling out. So, the results for API will be subdued in the second half against the first half," an analyst said.

Sun Pharma, on the other hand, saw its external sales of API fall by 10.5 per cent to ₹450 crore in the third quarter of FY21 on YoY basis over Q3 last year. For nine months, API sales of Sun Pharma were at ₹1,515 crore, up 5.7 per cent. However, the company said its API business imparted benefits of vertical integration and continuity of supply chain for its formulations business. "We continue to focus on increasing API supply for captive consumption for key products," the company said.

Alembic Pharmaceuticals' API business grew nearly 21 per cent YoY to ₹210 crore. According to experts, the demand opportunities are set to reduce.

"Demand opportunities have started to reduce, with supplies resuming from China. It is incrementally adding capacities to de-bottleneck its plants. The temporary spurt in prices seemed to have normalised," ICICI Securities said in its note on Alembic Pharma.

Biocon's generics business revenue was down 3 per cent to ₹561 crore, as its portfolio of statin APIs were impacted because of muted demand.

Zydus Cadila's net profit up 41% on India biz growth

VINAY UMARJI
Ahmedabad, 5 February

Led by a double-digit growth in its India business, Cadila Healthcare (Zydus Cadila) has reported 41 per cent increase in its consolidated net profit at ₹527.2 crore in the third quarter. The Ahmedabad-based drug maker's consolidated net profit was ₹373.9 crore in the year-ago period.

Its consolidated revenue from operations grew by 6.20 per cent in the third quarter to ₹3,753.7 crore against ₹3,534.5 crore in the same period in 2019-20.

The company's business in India comprising human health formulations, consumer wellness, and animal health increased 20 per cent year-on-year (YoY) during the quarter at ₹1,643 crore. Of these, while human health formulations business in India contributed 21 per cent to the company's growth, consumer wellness and animal health businesses grew 16 per cent and 17 per cent YoY, respectively.

However, Zydus Cadila's US formulations business declined 4 per cent YoY in the quarter with revenues of ₹1,603 crore against ₹1,675 crore in the year-ago quarter.

The third quarter saw Zydus file 10 additional abbreviated new drug applications with the US Food and Drug Administration taking the cumulative number of filings to 410. During the quarter, the firm launched the oral anti-diabetic agent, Dapaglyn in India for patients suffering from chronic obstructive pulmonary disorder.

Sales of Ivermectin, drug to treat parasitic infections, jump fourfold

SOHINI DAS & RUCHIKA CHITRAVANSHI
Mumbai/New Delhi, 5 February

Ivermectin, a drug used to treat parasitic infections, rose to prominence in 2020 as a treatment for Covid-19, pushing its sales up by more than 25 times, prompting more drug firms to launch the product.

Though demand for Ivermectin slowed with the rise of antivirals like remdesivir and favipiravir, experts feel its relevance as a prophylaxis remains. Annual sales of Ivermectin were around ₹19 crore in 2018 and went up to ₹21 crore in 2019. In 2020 it shot up to ₹94 crore. The drug's sales grew from ₹1.7 crore in April to ₹26.8 crore in September, riding on Covid-19 demand, shows data from market research firm AIOCD AWACS.

Mumbai-based pulmonologist Dr Agam Vora said in the first few months of the pandemic, the line of treatment was not established. "Ivermectin emerged as one of the better options around at the time as it has hardly any side effects and has no drug-to-drug interaction. It is inexpensive and easily available. The best part is its prophylactic properties," Dr Vora said. He has published papers on the role of Ivermectin in treating mild cases of Covid-19.



BOOSTER DOSE

Sales value (₹ crore)

Source: AIOCD AWACS

Dr Vora said by the time Ivermectin popularity grew, antivirals like favipiravir and remdesivir came along. This hit demand for the drug, which saw sales dip to ₹8.6 crore in December.

Several firms launched the drug last year, including Mumbai-based JB Chemicals. Nikhil Chopra, chief executive officer of JB Chemicals, said they launched the drug in November. It also launched favipiravir and Chopra feels Ivermectin has not lost its relevance as it has prophylactic properties.

Dr Vora said, "The vaccine would take some time to cover a sizeable population. Until then, safe drugs like Ivermectin can be used as prophylactic to stop the spread of infection."

Firms like Cipla, Sun Pharmaceuticals, Zuventus have popular Ivermectin brands in the market. Kedar Upadhye, global CFO of Cipla, too, said Ivermectin was considered good for Covid-19 before other molecules came along. Sales of the drug first picked up in states like Uttar Pradesh, West Bengal, and it still seems to be doing well in the North.

"We are giving Ivermectin to those who are getting admitted in the hospitals with Covid as well as family members and contacts of the patient... This is in the government protocol," said Subodh Kumar Adarsh, chief medical officer, Agra.

A chief medical officer in Aligarh said the drug, unlike HCQ, which was also a part of the protocol, does not have any major side effects and is easier to use. Medical professionals believe the repurposed drug controls the replication of the virus in the body. However, it works for mild cases and doesn't prevent deaths, a Delhi-based doctor said.

More vaccine candidates get nod for clinical trials

SOHINI DAS
Mumbai, 5 February

A bunch of Covid-19 vaccine candidates got approval from the expert panel to conduct clinical trials in India, including one from Novavax, Bharat Biotech's intra-nasal candidate, and a measles vector-based candidate from Zydus Cadila.

In its February 3 meeting, the subject expert panel (SEC) advising the Central Drugs Standard Control Organisation (CDSCO) recommended that approval be granted for conducting phase II/III clinical trials to Serum Institute of India (SII) for the Novavax candidate. This vaccine is based on protein nanoparticle and uses the proprietary Matrix-M adjuvant from Novavax. Adjuvants are pharmacological or immunological agents that improve the immune response of a vaccine.

The SEC has noted that participants randomised in the placebo arm may be un-blinded 60 days after the second dose, upon request from the clinical trial participant only. Blinded vaccine trials are those where the participant, investigator and sponsor do not know whether a person was given a vaccine or a placebo.


Trials will be held for vaccine candidate from Novavax, Bharat Biotech's intra-nasal candidate, and a measles vector-based candidate from Zydus

As for Bharat Biotech's chimpanzee flu virus (adenovirus) based intra-nasal vaccine candidate, the SEC recommended grant of permission for phase I trials.

Ahmedabad-based Zydus Cadila got approval for conducting phase I/II trials for the 2019-nCoV vaccine 3mg (two dose schedule). The SEC has noted that safety should be the primary objective of the study.

This is Zydus Cadila's second vaccine candidate, developed by its European research arm Etna Biotech. It is a live weakened recombinant measles virus vector-based vaccine against Covid-19. The genetically engineered measles virus vector would express proteins of the novel coronavirus and, thus, induce long-term specific neutralising antibodies.

Meanwhile, Aurobindo Pharmaceuticals has been asked to submit a revised clinical trial protocol for its vaccine candidate UB-612. The firm presented animal study and phase I data before the committee. The SEC recommended that Aurobindo submit the phase II/III clinical trial protocols approved by the regulatory authority of Brazil and some other conditions.

API sales momentum begins to normalise

SOHINI DAS & VINAY UMARJI
Mumbai/Ahmedabad, 5 February

Domestic drug market growth slows to 4.5% in January

After a robust performance in December, the domestic pharma market crawled back to a slower growth trend in January. Dragged by some therapy areas, the Indian Pharmaceutical Market (IPM) grew 4.5 per cent in January against an 8.5 per cent growth in December.

Cardiac therapy registered monthly growth of 8.8 per cent in January against 14.9 per cent in December, showed the data from market research firm AIOCD AWACS. Anti-diabetic, on the other hand, grew 5.3 per cent in January against 9.9 per cent growth in December. Among firms, Sun Pharmaceuticals grew 5.1 per cent while Lupin posted 4.6 per cent growth. Mankind did well at 9.3 per cent while Cipla growth came in at 4.2 per cent. SOHINI DAS

After witnessing a momentum in active pharmaceutical ingredients (API) sales on account of formulation/medicine makers stocking up during the pandemic, drug makers have begun to see some correction on a sequential basis.

With API supply, especially from China, facing some constraints because of lockdowns in several countries, demand from global clients had shot up for Indian players. This had led to a spurt in API sales in the first two quarters of FY21.

However, with global clients now having adequate inventory, the order growth is beginning to normalise or slowdown in certain cases. This is evident from the Q3 results of several pharma firms that show a sequential dip or muted growth in API sales after picking up significantly in the first half of the year.

For example, a leading API player — Dr Reddy's Laboratories (DRL) — has seen an 18 per cent drop in revenues from pharmaceutical services and active ingredients on a sequential basis in Q3, while on a year-on-year (YoY) basis the rise is 1 per cent. Erez Israeli, chief executive of DRL, said: "There has been an inventory accumulation by our customers in the first two quarters. Thus, there has been a dip now (in terms of demand). We are looking for more markets."

Mumbai-headquartered Cipla has managed to post growth sequentially, but the rate of growth has slumped. While on YoY basis, the API revenue grew 22 per cent, on quarter-on quarter (QoQ) it grew 7 per cent in Q3FY21.

Kedar Upadhye, global chief financial officer, Cipla, said the industry was stocking up APIs in the first half of FY21. "Part of this was due to Wuhan crisis and API shortage, while partly formulation players wanted to stock up APIs to avoid production disruption. We also stocked up. So, going forward the uptake of APIs will slow down a bit," he explained.

Lupin, too, has seen a dip in API sales on a sequential basis, around 8.1 per cent decline in Q3FY21 compared to the previous quarter. On YoY basis, however, it has grown 8.4 per cent. "There was a momentum in pharma industry in the first half of the financial year and global demand for APIs shot up. However, we will see that correction happening across the stocks as API demand is fizzling out. So, the results for API will be subdued in the second half against the first half," an analyst said.

Sun Pharma, on the other hand, saw its external sales of API fall by 10.5 per cent to ₹450 crore in the third quarter of FY21 on YoY basis over Q3 last year. For nine months, API sales of Sun Pharma were at ₹1,515 crore, up 5.7 per cent. However, the company said its API business imparted benefits of vertical integration and continuity of supply chain for its formulations business. "We continue to focus on increasing API supply for captive consumption for key products," the company said.

Alembic Pharmaceuticals' API business grew nearly 21 per cent YoY to ₹210 crore. According to experts, the demand opportunities are set to reduce.

"Demand opportunities have started to reduce, with supplies resuming from China. It is incrementally adding capacities to de-bottleneck its plants. The temporary spurt in prices seemed to have normalised," ICICI Securities said in its note on Alembic Pharma.

Biocon's generics business revenue was down 3 per cent to ₹561 crore, as its portfolio of statin APIs were impacted because of muted demand.

Zydus Cadila's net profit up 41% on India biz growth

VINAY UMARJI
Ahmedabad, 5 February

Led by a double-digit growth in its India business, Cadila Healthcare (Zydus Cadila) has reported 41 per cent increase in its consolidated net profit at ₹527.2 crore in the third quarter. The Ahmedabad-based drug maker's consolidated net profit was ₹373.9 crore in the year-ago period.

Its consolidated revenue from operations grew by 6.20 per cent in the third quarter to ₹3,753.7 crore against ₹3,534.5 crore in the same period in 2019-20.

The company's business in India comprising human health formulations, consumer wellness, and animal health increased 20 per cent year-on-year (YoY) during the quarter at ₹1,643 crore. Of these, while human health formulations business in India contributed 21 per cent to the company's growth, consumer wellness and animal health businesses grew 16 per cent and 17 per cent YoY, respectively.

However, Zydus Cadila's US formulations business declined 4 per cent YoY in the quarter with revenues of ₹1,603 crore against ₹1,675 crore in the year-ago quarter.

The third quarter saw Zydus file 10 additional abbreviated new drug applications with the US Food and Drug Administration taking the cumulative number of filings to 410. During the quarter, the firm launched the oral anti-diabetic agent, Dapaglyn in India for patients suffering from chronic obstructive pulmonary disorder.

Sales of Ivermectin, drug to treat parasitic infections, jump fourfold

SOHINI DAS & RUCHIKA CHITRAVANSHI
Mumbai/New Delhi, 5 February

Ivermectin, a drug used to treat parasitic infections, rose to prominence in 2020 as a treatment for Covid-19, pushing its sales up by more than 25 times, prompting more drug firms to launch the product.

Though demand for Ivermectin slowed with the rise of antivirals like remdesivir and favipiravir, experts feel its relevance as a prophylaxis remains. Annual sales of Ivermectin were around ₹19 crore in 2018 and went up to ₹21 crore in 2019. In 2020 it shot up to ₹94 crore. The drug's sales grew from ₹1.7 crore in April to ₹26.8 crore in September, riding on Covid-19 demand, shows data from market research firm AIOCD AWACS.

Mumbai-based pulmonologist Dr Agam Vora said in the first few months of the pandemic, the line of treatment was not established. "Ivermectin emerged as one of the better options around at the time as it has hardly any side effects and has no drug-to-drug interaction. It is inexpensive and easily available. The best part is its prophylactic properties," Dr Vora said. He has published papers on the role of Ivermectin in treating mild cases of Covid-19.

BOOSTER DOSE



Dr Vora said by the time Ivermectin popularity grew, antivirals like favipiravir and remdesivir came along. This hit demand for the drug, which saw sales dip to ₹8.6 crore in December.

Several firms launched the drug last year, including Mumbai-based JB Chemicals. Nikhil Chopra, chief executive officer of JB Chemicals, said they launched the drug in November. It also launched favipiravir and Chopra feels Ivermectin has not lost its relevance as it has prophylactic properties.

Dr Vora said, "The vaccine would take some time to cover a sizeable population. Until then, safe drugs like Ivermectin can be used as prophylactic to stop the spread of infection."

Firms like Cipla, Sun Pharmaceuticals, Zuventus have popular Ivermectin brands in the market. Kedar Upadhye, global CFO of Cipla, too, said Ivermectin was considered good for Covid-19 before other molecules came along. Sales of the drug first picked up in states like Uttar Pradesh, West Bengal, and it still seems to be doing well in the North.

"We are giving Ivermectin to those who are getting admitted in the hospitals with Covid as well as family members and contacts of the patient... This is in the government protocol," said Subodh Kumar Adarsh, chief medical officer, Agra.

A chief medical officer in Aligarh said the drug, unlike HCQ, which was also a part of the protocol, does not have any major side effects and is easier to use. Medical professionals believe the repurposed drug controls the replication of the virus in the body. However, it works for mild cases and doesn't prevent deaths, a Delhi-based doctor said.

जाहीर सूचना - आयडी कार्ड हरवले

ICICI Bank
ICICI Bank Limited

सदर सर्वसामान्य जनतेच्या माहितीसाठी आहे की, **आयडी कार्ड क्र.०१३८६ व ००८३७** असलेले आयसीआयसीआय बँक लि.ने जारी केलेले **श्री. विजय राऊण जमादार व साहेब रामाश्रय मौर्या** यांचे एक आयडीकार्ड हे ०४.०२.२०२१ रोजी हरवले आहे. कोणाला सापडल्यास मॅनेजर, डेस्ट सर्व्हिसेस अँण्ड मॅनेजमेंट ग्रुप, आयसीआयसीआय बँक लिमिटेड, १ला मजला, सी विंग, चांदिवली स्टुडिओजवळ, अंधेरी (पुर्व), मुंबई-४०००७२ येथे पाठवावे. त्यामुळे आयसीआयसीआय बँक लिमिटेडच्या सर्व ग्राहकांना याद्वारे सुचित करण्यात येते की, आयडी कार्ड क्र.०१३८६ व ००८३७ धारक कोणत्याही अनधिकृत व्यक्तिला कोणतेही प्रदान करू नये. कृपया पुढे सूचना घ्यावी की, कोणीही सदर आयडी कार्डधारक कोणत्याही व्यक्तिला प्रदान करीत असल्यास त्यांनी/तिनी स्वत:चा खर्च, जोखीम आणि परिणामांवर तसे करावे आणि आयसीआयसीआय बँक कोणत्याही प्रदानासाठी बंधनकारक आणि/किंवा जबाबदार राहणार नाही.

आयसीआयसीआय बँक लिमिटेडकरिता
दिनांक: ०६/०२/२०२१ ठिकाण: मुंबई

TO WHOMSOEVER IT MAY CONCERN

I state that my true and correct name is **Bhoomi Atul Shah** which is mentioned in my Aadhar Card and in my Marksheet my name is recorded as **Shah Bhoomi Atulkumar**.

I state that both the names i.e. **Shah Bhoomi Atulkumar** and **Bhoomi Atul Shah** belongs to same and one person i.e. myself. (As per Affidavit dtd. 04/02/2021).

Sd/-
Bhoomi Atul Shah

एव्हीटीआयएल एंटरप्राईज लिमिटेड

CIN:L70100MH1982PLC027263
नोंदणीकृत कार्यालय: १/२०४, नवजीवन सोसायटी, लॅमिंग्टन रोड, मुंबई-४००००८.
दूर.:०२२-२३०७५६७७, E-mail:info@avtradeinvest.com
Website: www.avtradeinvest.com

सूचना

सेबी (लिस्टिंग ऑब्लिगेशन्स अँण्ड डिस्क्लोजर रिक्वायरमेंट्स) रेग्युलेशन्स २०१५ च्या नियम ४७(१) नुसार येथे सूचना देण्यात येत आहे की, ३१ डिसेंबर, २०२० रोजी संपलेल्या तिमाही व नऊमाहीकरिता अलेखापरिक्षित वित्तीय निष्कर्ष विचारात घेणे व मान्यता देणे याकरिता कंपनीच्या नोंदणीकृत कार्यालयात शनिवार, १३ फेब्रुवारी, २०२१ रोजी दु.४.००वा. कंपनीच्या संचालक मंडळाची सभा होणार आहे.

नियम ४७(२) नुसार सदर सूचना कंपनीच्या www.avtradeinvest.com वेबसाईटवर व बीएसई लिमिटेडच्या www.bseindia.com वेबसाईटवर उपलब्ध आहे.

एव्हीटीआयएल एंटरप्राईज लिमिटेडकरिता
सही/-
दिनांक: ०५.०२.२०२१
ठिकाण: मुंबई
धर्मिका दर्जी
कंपनी सचिव व सक्षम अधिकारी

इंडियन इन्फोटेक अँण्ड सॉफ्टवेअर लिमिटेड

नोंदणीकृत कार्यालय: चेंबर क्र.३ व ४, ७वा मजला, स्कायलाईन आयकॉन, अंधेरी-कुर्ला रोड, चिमटपाडा, मरोळ, अंधेरी (पुर्व), मुंबई-४०००५९.
सीआयएन:एल७०१००एमएच१९८२पीएलसी०२७१९८
ई-मेल:indianinfotechsoftware@yahoo.com
वेबसाईट: www.iisfinance.com

सूचना

सेबी (लिस्टिंग ऑब्लिगेशन्स अँण्ड डिस्क्लोजर रिक्वायरमेंट्स) रेग्युलेशन्स २०१५ च्या नियम ४७(१)(अ) नुसार येथे सूचना देण्यात येत आहे की, ३१ डिसेंबर, २०२० रोजी संपलेल्या तिमाही व नऊमाहीकरिता कंपनीचे लेखापरिक्षित वित्तीय निष्कर्ष तसेच त्यावरील लेखापरिक्षकांचा अहवाल विचारात घेणे व मान्यता देणे याकरिता कंपनीच्या नोंदणीकृत कार्यालय- चेंबर क्र.३ व ४, ७वा मजला, स्कायलाईन आयकॉन, अंधेरी-कुर्ला रोड, चिमटपाडा, मरोळ, अंधेरी (पुर्व), मुंबई-४०००५९ येथे शनिवार, १३ फेब्रुवारी, २०२१ रोजी सायं.५.००वा. कंपनीच्या संचालक मंडळाची सभा होणार आहे.

इंडियन इन्फोटेक अँण्ड सॉफ्टवेअर लिमिटेडकरिता
सही/-
श्यामा चरण कुमार
ठिकाण : मुंबई व्यवस्थापकीय संचालक
दिनांक : ०५.०२.२०२१ डीआयएन:००४९४२९७

मैस्ट्रॉस इलेक्ट्रॉनिक्स अँण्ड टेलिकम्युनिकेशन्स सिस्टिम्स लिमिटेड

सीआयएन:एल७४९००एमएच२०१०पीएलसी२००२५४
नोंदणीकृत कार्यालय: प्लॉट क्र.ईएल-६६, इलेक्ट्रॉनिक झोन, टीटीसी इंडस्ट्रियल एरिया, महापे, नवी मुंबई-४००७१०.
दूर.:०२२-२७६१११९३/९४, फॅक्स:०२२-२७६१००९३.
ई-मेल:tendulkar@metsl.in
वेबसाईट:www.maestroselectronics.com

सूचना

येथे सूचना देण्यात येत आहे की, सेबी (लिस्टिंग ऑब्लिगेशन्स अँण्ड डिस्क्लोजर रिक्वायरमेंट्स) रेग्युलेशन्स २०१५ च्या नियम ४७ सहवाचिता नियम ३३ नुसार ३१ डिसेंबर, २०२० रोजी संपलेल्या तिमाही व नऊमाहीकरिता कंपनीचे मर्यादित पुनर्विलोकन अहवालासह अलेखापरिक्षित वित्तीय निष्कर्ष अहवाल विचारात घेणे, मान्यता देणे व नोंद पटावर घेणे याकरिता प्लॉट क्र.ईएल-६६, इलेक्ट्रॉनिक झोन, टीटीसी इंडस्ट्रियल एरिया, महापे, नवी मुंबई-४००७१० येथे **शुक्रवार, १२ फेब्रुवारी, २०२१** रोजी दु.२.३०वा. **मैस्ट्रॉस इलेक्ट्रॉनिक्स अँण्ड टेलिकम्युनिकेशन्स सिस्टिम्स लिमिटेड**च्या संचालक मंडळाची सभा होणार आहे.

मैस्ट्रॉस इलेक्ट्रॉनिक्स अँण्ड टेलिकम्युनिकेशन्स सिस्टिम्स लिमिटेडकरिता
सही/-
ठिकाण : नवी मुंबई बाळकृष्ण तेंडुलकर
दिनांक : ०६.०२.२०२१ व्यवस्थापकीय संचालक

PIONEER INVESTCORP LIMITED

((CIN L65990MH1984PLC031909)
Regd. off.:- 1218, Maker Chambers V, Nariman Point, Mumbai - 400021.
Tel. no. 022- 6618 6633
Fax no. 022 - 2204 9195
Website: www.pinc.co.in

NOTICE

NOTICE is hereby given that pursuant to Regulation 29 read with Regulation 47 of SEBI (Listing Obligation and Disclosure Requirements) Regulations, 2015, meeting of the Board of Directors of the Company is scheduled to be held on Thursday, February 11th, 2021, to consider and approve the Unaudited Standalone and Consolidated Financial Results of the Company for third quarter and nine months period ended on 31st December, 2020.

This intimation is also available on the website of the Company at www.pinc.co.in and on the website of the BSE where the shares of the Company are listed at www.bseindia.com

FOR PIONEER INVESTCORP LIMITED
Sd/-
AMIT CHANDRA
COMPANY SECRETARY
Place : Mumbai.
Date : 5th February, 2021

ऑथम इन्व्हेस्टमेंट अँण्ड इन्फ्रास्ट्रक्चर लिमिटेड

सीआयएन:एल५११०९एमएच१९८२पीएलसी३१९००८
ई-मेल: info@authum.com,
वेबसाईट: www.authum.com
दुर.क्र.: ०२२-६७४७२११७
नोंदणीकृत कार्यालय: ७०७, रहेजा सेंटर, फ्रि प्रेस जर्नल मार्ग, नरिमन पॉईंट, मुंबई-४०००२१.

सूचना

सेबी (लिस्टिंग ऑब्लिगेशन्स अँण्ड डिस्क्लोजर रिक्वायरमेंट्स) रेग्युलेशन्स २०१५ च्या नियम २९ व ४७ नुसार येथे सूचना देण्यात येत आहे की, ३१ डिसेंबर, २०२० रोजी संपलेल्या तिमाही व नऊमाहीकरिता अलेखापरिक्षित वित्तीय निष्कर्ष विचारात घेणे व मान्यता देणे आणि इतर संबंधित प्रकरणे याकरिता शुक्रवार, १२ फेब्रुवारी, २०२१ रोजी कंपनीच्या संचालक मंडळाची सभा होणार आहे.

सदर सूचना कंपनीच्या www.authum.com वेबसाईटवर आणि कंपनीचे शेअर्स जेथे सूचिबध्द आहेत त्या स्टॉक एक्सचेंजच्या www.bseindia.com वेबसाईटवर उपलब्ध आहे.

ऑथम इन्व्हेस्टमेंट अँण्ड इन्फ्रास्ट्रक्चर लिमिटेडकरिता
दिनांक : ०५.०२.२०२१ सही/-
ठिकाण : मुंबई हितेश वोरा
कंपनी सचिव व सक्षम अधिकारी

शुद्धिपत्रक

वकील पदम जालन यांच्याद्वारे पृष्ठ क्र.५ वर मुंबई लक्षदीपमध्ये दिनांक ०४.०२.२०२१ रोजी प्रकाशित जाहीर सूचना या जाहिरातीसंदर्भात. खरेदीदार अतुल शाह यांचे पत्ताभवील पीन कोड क्रमांक ४०१६०४ या ऐवजी ४०१३०४ असे चुकीने नमूद केले आहे.
योग्य पत्ता खालीलप्रमाणे:
श्री. अतुल शाह, आरएच ५ प्रतिक कोहीसोलि., कुसुमाग्रज मार्ग, ठाणे-४००६०४.
वाचकांना झालेल्या गैरसोयीबद्दल दिलगिरी.

इंडिया होम लोन लिमिटेड

(सीआयएन:एल६५९१०एमएच१९९०पीएलसी०५९४९९)
नोंदणीकृत कार्यालय: ५०४/५०४ए, ५वा मजला, निर्मल एक्टाशी, जटाशंकर डोसा रोड, मुलुंड(प), मुंबई, महाराष्ट्र-४०००८०.
ई-मेल:cs@indiahomeloan.co.in
वेबसाईट: www.indiahomeloan.co.in

सूचना

सेबी (लिस्टिंग ऑब्लिगेशन्स अँण्ड डिस्क्लोजर रिक्वायरमेंट्स) रेग्युलेशन्स २०१५ च्या नियम २९ सहवाचिता नियम ४७(१)(अ) नुसार येथे सूचना देण्यात येत आहे की, ३१ डिसेंबर, २०२० रोजी संपलेल्या तृतीय तिमाही व नऊमाहीकरिता कंपनीचे अलेखापरिक्षित वित्तीय निष्कर्ष विचारात घेणे व मान्यता देणे याकरिता १२ फेब्रुवारी, २०२१ रोजी कंपनीच्या संचालक मंडळाची सभा होणार आहे.

सदर सूचना समाविष्ट माहिती कंपनीच्या www.indiahomeloan.co.in वेबसाईटवर आणि कंपनीचे शेअर्स जेथे सूचिबध्द आहेत त्या मुंबई स्टॉक एक्सचेंजच्या www.bseindia.com वेबसाईटवर उपलब्ध आहे.

मंडळाच्या आदेशान्वये
इंडिया होम लोन लिमिटेडकरिता
सही/-
ठिकाण: मुंबई नितेश एम. पुजारा
दिनांक: ०६.०२.२०२१ पुर्णवेळ संचालक

THOMAS SCOTT (INDIA) LIMITED

CIN: L18109MH2010PLC209302
Authorised Cap: Rs. 50,000,000/-
Subscribed Cap: Rs. 33,900,000/-
Paid up Cap: Rs. 33,900,000/-
Regd. Off: 50, Kewal Industrial Estate, Senapati Bapat Marg, Lower Parel (West), Mumbai-400013
Email: investor.ts@banggroup.com
Website: www.thomasscott.org
Corp. Off: 405-406, Kewal Industrial Estate, Senapati Bapat Marg, Lower Parel (West), Mumbai- 400 013

NOTICE

NOTICE is hereby given that, pursuant to Regulation 29 read with Regulation 47 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, that the 04/2020-21 Meeting of Board of Directors of the Company is scheduled to be held on Saturday, 13th February, 2021 at 02.15 p.m. at the Corporate Office of the Company situated at "405-406, Kewal Industrial Estate, Senapati Bapat Marg, Lower Parel (West), Mumbai-400013" to consider and approve the Un-audited Financial Results for the quarter & nine months ended 31st December, 2020. The said Notice may be accessed on the Company's Website at www.thomasscott.org and also on the Stock Exchange Website at www.bseindia.com and www.nseindia.com.

For Thomas Scott (India) Limited
Sd/-
Brijgopal Bang
Director - DIN : 00112203
Place : Mumbai
Date : 05/02/2021

PUBLIC NOTICE

NOTICE is hereby given to the public at large that my clients MRS. GEETA VINOD MALAVIA is the OWNER (Donee) of the Premises located at Santacruz (East), Gitanjali (Santacruz East) Co-Operative Housing Society Ltd.(Registration No. BOM/HSG 3216 OF 1971) (hereinafter referred to as "the said Society") situated at Flat No.7, Ground Floor, Gitanjali (Santacruz East) Co- Operative Housing Society Ltd. 3 J. Nehru Nagar, Santacruz (East) Mumbai – 400055 (said Premises") together with 5 fully paid up shares of Rs.50/- each of the said Society, bearing Distinctive Nos. 31 to 35 (both inclusive) incorporated in the Share Certificate No. 7 , No. of transfer -1, Ledger Folio-21 SR. NO.67 (hereinafter referred to as "the said Shares"). The chain of documents in respect of the said Premises is (I) The First Agreement dated 24th MARCH 1972, was Taken over by Mrs Veena Roy and Mr.Gopesh Chandra Roy, (II) The Second transfer on dated 19th FEBRUARY 2012 through Mgm Comittee Meeting to Mrs. Madhuri Toofan Roy (daughter in law of Mrs. Veena Roy and Mr. Gopesh Chandra Roy) (III) The Third GIFT DEED dated 16th OCTOBER 2014 was executed between Mrs. Madhuri Toofan Roy (The DONOR) and Mrs Geeta Vinod Malavia(The DONEE) i.e. my clients. My client's son Mr. Pinkesh Vinod Malavia lodge F.I.R. NO. 280 Dated 22/01/21 at Vakola Police Station , Santacruz (E).Mumbai. The said Original First Agreement in respect of the said Premises is lost / misplaced and even after the diligent search the same is not traceable. If any person/s/ Bank / Financial Institutions having custody of the said Original First Agreement in respect of the said Premises or any right, title, interest, claim/s or demand upon against or in respect thereof, whether by way of sale, exchange, mortgage, charge, lease license attachment, gift, trust, inheritance or otherwise howsoever, are hereby required to make the same known to me in writing with documentary evidence at my address mentioned below within 14 (fourteen) days from the date of publication hereof, failing which it shall be considered that there exists no such claims or demands in respect of the said Premises and then the claims or demands if any, of such person/s shall be deemed as waived and abandoned to all intents and purposes and the title of the said Premises shall be presumed as clear, marketable and free from all encumbrances.
Mumbai, Dated this 6th day of February 2021.

Sd/-
GEETA R. PATEL
Advocate of High Court
25/195, Anand Nagar
Om Co-op. Soc. Hsg. Ltd.,
Nehru Road,Vakola Bridge,
Santacruz (East),
Mumbai – 400 055

नोटीस

एकता एस. आर. ए. सहकारी गृहनिर्माण संस्था मर्यादित. इमारत क बी/३, लोहिया नगर, एल. आय. सी. कॉलनीच्या मागे, वेस्ट. हायवेस रोड, विलेपार्ले (पश्चिम), मुंबई - ४०० ०५६.या संस्थेचे सभासद असलेल्या व संस्थेच्या इमारतीत सदनिका क्र. ४०४ धारण करणारे श्रेमती डेबोड डिसोझा (संस्थेत नोंद असलेले पूर्ण नाव - डेबीड पिटर डिसोझा) यांचे तारीख १३-०१-२०१२ रोजी निधन झाले. त्यांनी नामनिर्देशन केलेले नाही. संस्था, या सोटीद्वारे संस्थेच्या भांडवलात/मालमत्तेत असलेले मयत सभासदाचे भाग व हितसंबंध हस्तांतरित करण्यासंबंधी मयत सभासदाच्या वारसदार किंवा अन्य मागणीदार/हरकतदार यांच्याकडून हक्क, मागण्या/हरकती मागविण्यात येत आहेत. ही नोटीस प्रसिद्ध झाल्याच्या तारखेपासून १४ दिवसात त्यांनी आपल्या मागण्यांच्या वा हरकतीच्या पुष्ठ्यर्थ आवश्यक त्या कागदपत्रांच्या प्रती व अन्य पुरावे सादर करावेत. जर वर नमूद केलेल्या मुदतीत, कोणाही व्यक्तीकडून हक्क मागण्या किंवा हरकती सादर झाल्या नाही तर, मयत सभासदाचे संस्थेच्या भांडवलातील/मालमत्तेतील भाग व हितसंबंध यांच्या हस्तांतरणाबाबत संस्थेच्या उपविधीनुसार कार्यवाही करण्याची संस्थेला मोकळीक राहील. जर अशा कोणत्याही हक्क, मागण्या/हरकती आल्या तर, त्याबाबत संस्थेच्या उपविधीनुसार कार्यवाही करण्यात येईल. नोंदी वी उपविधीची एक प्रत मागणीदारांस / हरकतदारांस पाहण्यासाठी संस्थेच्या कार्यालयात सचिव यांच्याकडे सकाळी ८:३० ते १०:३० वाजेपर्यंत, नोटीस दिलेल्या तारखेपासून नोटीशीची मुदत संपण्याच्या तारखेपर्यंत उपलब्ध राहील.
ठिकाण: मुंबई. दिनांक: ०६/०२/२०२१
एकता एस. आर. ए. सहकारी गृहनिर्माण संस्था मर्यादित यांच्या करिता आणि वतीने
सही/-
सचिव

PROZONE INTU PROPERTIES LIMITED

Regd. Off: 105/106, Ground Floor, Dream Square, Dalia Industrial Estate, Off New Link Road, Andheri (West), Mumbai - 400 053
CIN : L45200MH2007PLC174147 | Website: www.prozoneintu.com |Ph: +91-22-68239000

NOTICE

NOTICE is hereby given pursuant to Regulation 47 of SEBI (Listing Obligations and Disclosure Requirements) Regulations 2015, that a meeting of the Board of Directors of the Company is scheduled to be held on Friday, the 12th February, 2021 interalia, to consider and approve the Unaudited standalone and consolidated financial Results of the Company for the quarter ended 31st December 2020.

This intimation shall be available on the website of the Company at www.prozoneintu.com and on the website of the Stock Exchanges where the shares of the Company are listed i.e. www.bseindia.com and www.nseindia.com.

For Prozone Intu Properties Limited
Sd/-
Date : 05.02.2021 Ajayendra P. Jain
Place : Mumbai CS & Chief Compliance Officer

HARIYANA SHIP BREAKERS LTD

CIN NO. L61100MH1981PLC024774
नोंदणीकृत कार्यालय: १५६, मेकर चेंबर्स ६, २२० जमनालाल बजाज मार्ग, नरिमन पॉईंट, मुंबई-४०००२१.
दूरध्वनी:०२२-२२०४३२११, फॅक्स:०२२-२२०४३२१५,
ई-मेल:secretarial.hariyana@gmail.com वेबसाईट:www.hariyanagroup.com
ISO Certified (14001:2004/9001:2008/30000:2009)

सूचना

सेबी (लिस्टिंग ऑब्लिगेशन्स अँण्ड डिस्क्लोजर रिक्वायरमेंट्स) रेग्युलेशन्स २०१५ च्या नियम २९(१)(अ) सहवाचिता नियम ४७(१)(अ) नुसार येथे सूचना देण्यात येत आहे की, ३१ डिसेंबर, २०२० रोजी संपलेल्या तिमाही व नऊमाहीकरिता अलेखापरिक्षित एकमेव व एकत्रित वित्तीय निष्कर्ष त्यावरील मर्यादित पुनर्विलोकन अहवाल विचारात घेणे व मान्यता देणे याकरिता कंपनीच्या नोंदणीकृत कार्यालय-१५६, मेकर चेंबर्स ६, २२० जमनालाल बजाज मार्ग, नरिमन पॉईंट, मुंबई-४०००२१ येथे **शनिवार, १३ फेब्रुवारी, २०२१** रोजी सायं.५.३०वा. होणार आहे.

हरियाणा शिप-ब्रेकर्स लिमिटेडकरिता
सही/-
शांतीस्वरुप रामकुमार रेणीवाल
ठिकाण : मुंबई संचालक
दिनांक : ०५.०२.२०२१ डीआयएन:०००४०३५५

INDUCTO STEELS LTD

CIN NO. L27100MH1988PLC194523
कॉर्पोरेट कार्यालय: १५६, मेकर चेंबर्स ६, २२०, जमनालाल बजाज मार्ग, नरीमन पॉईंट, मुंबई-४०००२१. दूर.:०२२-२२०४३२११, फॅक्स:०२२-२२०४३२१५,
वेबसाईट:www.hariyanagroup.com, ई-मेल:secretarial.inducto@gmail.com
ISO 9001-2008/14001-2004 & OHSAS 18001-2007Certified

सूचना

सेबी (लिस्टिंग ऑब्लिगेशन्स अँण्ड डिस्क्लोजर रिक्वायरमेंट्स) रेग्युलेशन्स २०१५ च्या नियम २९(१)(अ) सहवाचिता नियम ४७(१)(अ) नुसार येथे सूचना देण्यात येत आहे की, ३१ डिसेंबर, २०२० रोजी संपलेल्या तिमाही व नऊमाहीकरिता लेखापरिक्षकांच्या अहवालासह एकमेव व एकत्रित अलेखापरिक्षित वित्तीय निष्कर्ष विचारात घेणे व मान्यता देणे याकरिता **शनिवार, १३ फेब्रुवारी, २०२१** रोजी दु.४.३०वा. कंपनीचे नोंदणीकृत कार्यालय-१५६, मेकर चेंबर्स ६, २२० जमनालाल बजाज मार्ग, नरिमन पॉईंट, मुंबई-४०००२१ येथे कंपनीच्या संचालक मंडळाची सभा होणार आहे.

इंडक्टो स्टील्स लिमिटेडकरिता
सही/-
दिनांक: ०५.०२.२०२१ रुपाली राजकुमार सोमानी
ठिकाण: मुंबई कंपनी सचिव व सक्षम अधिकारी (सदस्यत्व क्र.:ए१९५६१)

मंगल क्रेडीट अँण्ड फीनकॉर्प लिमिटेड

सीआयएन:एल६५९९०एमएच१९६१पीएलसी०१२२२७
नोंद.कार्यालय: १७०१/१७०२, १७वा मजला, ए विंग, लोटस कॉर्पोरेट पार्क, पश्चिम द्रुतगती महामार्ग, गोरेगाव (पुर्व), मुंबई-४०००६३. दूर.:०२२-४२४६१३००,
ई-मेल:compliance@mangalfincorp.com, वेबसाईट: www.mangalfincorp.com

सूचना

सेबी (लिस्टिंग ऑब्लिगेशन्स अँण्ड डिस्क्लोजर रिक्वायरमेंट्स) रेग्युलेशन्स २०१५ च्या नियम २९ सहवाचिता नियम ४७ नुसार येथे सूचना देण्यात येत आहे की, **३१ डिसेंबर, २०२०** रोजी संपलेल्या तिमाही व नऊमाहीकरिता कंपनीचे अलेखापरिक्षित वित्तीय निष्कर्ष विचारात घेणे व मान्यता देणे याकरिता **शुक्रवार, १२ फेब्रुवारी, २०२१** रोजी कंपनीच्या संचालक मंडळाची सभा होणार आहे.

मंगल क्रेडीट अँण्ड फीनकॉर्प लिमिटेडकरिता
सही/-
मेघराज जैन
दिनांक: ०५.०२.२०२१ व्यवस्थापकीय संचालक
ठिकाण: मुंबई डीआयएन:०१३११०४१

व्हीसीयू डाटा मॅनेजमेंट लिमिटेड

सीआयएन:एल७४१२०एमएच२०१३पीएलसी२४०४१८
नोंदणीकृत कार्यालय: ३०१, ३रा मजला, राजदीप इमारत, तारा टेम्पल लेन, लॅमिंग्टन रोड, मुंबई-४००००७. दूरध्वनी:०२२-४००४४१२५, ई-मेल:mumbai.vcudata@gmail.com
वेबसाईट: www.vcupack.in

सूचना

सेबी (लिस्टिंग ऑब्लिगेशन्स अँण्ड डिस्क्लोजर रिक्वायरमेंट्स) रेग्युलेशन्स २०१५ च्या नियम २९(१) आणि सहवाचिता नियम ४७(१) नुसार येथे सूचना देण्यात येत आहे की, ३१ डिसेंबर, २०२० रोजी संपलेल्या तिमाही व नऊमाहीकरिता कंपनीचे एकमेव व एकत्रित अलेखापरिक्षित वित्तीय निष्कर्ष विचारात घेणे व मान्यता देणे याकरिता **शनिवार, १३ फेब्रुवारी, २०२१** रोजी कंपनीच्या संचालक मंडळाची सभा होणार आहे.

सदर सूचना कंपनीच्या www.vcupack.in वेबसाईटवर तसेच मुंबई स्टॉक एक्सचेंजच्या www.bseindia.com वेबसाईटवर उपलब्ध आहे.

संचालक मंडळाच्या आदेशान्वये
व्हीसीयू डाटा मॅनेजमेंट लिमिटेडकरिता
सही/-
श्रीपाल बाफना
ठिकाण : मुंबई व्यवस्थापकीय संचालक
दिनांक : ०५.०२.२०२१ डीआयएन:०६४८९८२२

BANSWARA SYNTEX LIMITED

CIN - L24302RJ1976PLC001684
Regd. Office: Industrial Area, Dahod Road, P.B. No. 21, Banswara (Raj.)-327001
Ph. No.: 02962- 240690, 257679 – 681, Fax:02962- 240692
Website: www.banswarasyntex.com, Email: secretarial@banswarasyntex.com

NOTICE

Notice is hereby given pursuant to Regulation 47 of Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015, the Meeting of the Board of Directors of the Company will be held on Saturday, 13th February, 2021 at 12.00 Noon at Registered Office of the Company inter alia to approve the Unaudited Financial Results for the Quarter/nine months ended on 31st December 2020, if any. This information is available under the "Investor section of the company's website i.e. www.banswarasyntex.com and also websites of BSE Ltd. (http://www.bseindia.com) and National Stock Exchange of India Ltd. (http://www.nseindia.com).

By order of the Board
Banswara Syntex Ltd.
Sd/-
Place : Banswara H.P. Kharwal
Date : 5th February, 2021 Company Secretary

रिशीरूप लिमिटेड

सीआयएन: एल२५२००एमएच१९८४पीएलसी०३४०९३
नोंदणीकृत कार्यालय: डब्ल्यु ७५(ए) व डब्ल्यु ७६(ए), एमआयडीसी इंडस्ट्रियल एरिया, सातपूर, नाशिक-४२२००७.
मुख्य कार्यालय : ८४, अटलांटा, नरिमन पॉईंट, मुंबई-४०००२१.
वेबसाईट:www.rishiroop.in, ई-मेल:investor@rishiroop.com
दूर.:०२२-४०९५२०००

सूचना

कंपनी कायदा २०१३ च्या कलम ९१ नुसार येथे सूचना देण्यात येत आहे की, ५ फेब्रुवारी, २०२१ रोजी झालेल्या सभेत संचालक मंडळाद्वारे घोषितप्रमाणे वित्तीय वर्ष २०२०-२०२१ करिता रू.१०/- प्रत्येकीचे (अर्थात ५०%) रू.५.०० प्रती समभाग दराने अंतरिम लाभांश देण्याच्या उद्देशाकरिता नोंद दिनांक म्हणून १९ फेब्रुवारी, २०२१ निश्चित करण्यात आलेले आहे.

लाभांश, घोषित झाल्यास ज्या भागधारकांची नावे १९ फेब्रुवारी, २०२१ रोजी कंपनीचे सदस्य नोंद पुस्तक/लाभार्थी मालकांच्या यादीत नमुद आहेत त्यांना दिले जाईल.

सदर माहिती कंपनीच्या www.rishiroop.in/investors वेबसाईटवर आणि कंपनीचे शेअर्स सूचिबद्ध असलेल्या स्टॉक एक्सचेंजेस www.bseindia.com वेबसाईटवर उपलब्ध आहे.

मंडळाच्या आदेशान्वये
रिशीरूप लिमिटेडकरिता
सही/-
ठिकाण: मुंबई अँड्रेो ए. फर्नांडिस
दिनांक: ०५.०२.२०२१ कंपनी सचिव

रोझ मर्क लिमिटेड

सीआयएन:एल२४११०एमएच१९८५पीएलसी३५०७८
नोंदणीकृत कार्यालय: कार्यालय क्र.जी-२, तळमजला, भाग-९, मंगल महेश कोहीनो., १४वा रोड, खार (पश्चिम), मुंबई, महाराष्ट्र-४०००५२.
ई-मेल:rmltd1985@gmail.com

सूचना

येथे सूचना देण्यात येत आहे की, सेबी (लिस्टिंग ऑब्लिगेशन्स अँण्ड डिस्क्लोजर रिक्वायरमेंट्स) रेग्युलेशन्स २०१५ च्या नियम २९ सहवाचिता नियम ४७ नुसार ३१ डिसेंबर, २०२० रोजी संपलेल्या तृतीय तिमाहीकरिता कंपनीचे अलेखापरिक्षित एकमेव वित्तीय निष्कर्ष विचारात घेणे, मान्यता देणे याकरिता सेबी (लिस्टिंग ऑब्लिगेशन्स अँण्ड डिस्क्लोजर रिक्वायरमेंट्स) रेग्युलेशन्स २०१५ च्या नियम ३३ नुसार कंपनीचे नोंदणीकृत कार्यालय-कार्यालय क्र.जी-२, तळमजला, भाग-९, मंगल महेश कोहीनो., १४वा रोड, खार (पश्चिम), मुंबई, महाराष्ट्र-४०००५२ येथे **शुक्रवार, १२ फेब्रुवारी, २०२१** रोजी दु.३.००वा. कंपनीच्या संचालक मंडळाची सभा होणार आहे.

पुढे सेबी (आतील व्यापार रोखणे) अधिनियम २०१५ सहवाचिता कंपनीच्या कोड ऑफ कन्डक्ट नुसार आणि कंपनीच्या अंतर्गत व्यापार नियमन, नियंत्रण आणि अहवाल यासह कंपनीचे समभाग व्यवहाराचे व्यापार खिडकी विहित व्यक्ति यांच्याकरिता निष्कर्ष घोषणेनंतर ४८ तास समाप्तीनंतर अर्थात १४ फेब्रुवारी, २०२१ पर्यंत बंद ठेवण्यात येईल.

सेबी (लिस्टिंग ऑब्लिगेशन्स अँण्ड डिस्क्लोजर रिक्वायरमेंट्स) रेग्युलेशन्स २०१५ च्या नियम ४७ नुसार उपरोक्त सूचना कंपनीच्या www.rosemercltd.com आणि स्टॉक एक्सचेंज लिमिटेड अर्थात बीएसई लिमिटेडच्या www.bseindia.com वेबसाईटवर उपलब्ध आहे.

रोझ मर्क लिमिटेडकरिता
सही/-
कित्री सावला
ठिकाण : मुंबई व्यवस्थापकीय संचालक
दिनांक : ०५.०२.२०२१ डीआयएन:०२०७३७८९

किसान मोल्डिंग्ज लिमिटेड

(CIN: L17120MH1989PLC054305)
नोंदणीकृत कार्यालय : टेक्स सेंटर, के विंग, ३ रा मजला, २६ ए, चांदिवली रोड, साकीविहार रोड, अंधेरी (पुर्व), मुंबई - ४०० ०७२.दूर. क्र. ०२२-४२००९१००/९२००, फॅक्स : ०२२-२८४७८५०८
ई-मेल:cs.kisan@kisangroup.com, वेबसाईट: www.kisangroup.com

सूचना

सेबी (सूची अनिवार्यता व विमोचन आवश्यकता) विनियमन, २०१५ च्या नियम २९ व ४७ अंतर्गत येथे सूचना देण्यात येत आहे की, ३१ डिसेंबर, २०२० रोजी संपलेल्या तिसऱ्या तिमाही आणि नऊ महिने पर्यंतचे कंपनीचे अलेखापरिक्षित वित्तीय निष्कर्ष विचारात घेणे व मान्यता देणे या करिता शुक्रवार, दि. १२ फेब्रुवारी, २०२१ रोजी कंपनीच्या संचालक मंडळाची सभा होणार आहे.

या पुढे सदर सूचना कंपनीच्या वेबसाईटवर www.kisangroup.com आणि स्टॉक एक्सचेंजचे वेबसाईटवर www.bseindia.com उपलब्ध आहे.

किसान मोल्डिंग्ज लिमिटेड करिता
सही/-
ठिकाण : मुंबई संजीव अगरवाल
दिनांक : ०५/०२/२०२१ अध्यक्ष व व्यवस्थापकीय संचालक

PUBLIC NOTICE

Notice is hereby given that My client, was going to Nallasopara Station, and my Client's Original Agreement lost in Auto Rickshaw on Dated 04/02/2021, time approx 11.00 am. Between Mr. Babaria Dewshi Premji & M/s. Anant Ashray, Doc No. Chha4030/1999/VSI2, Agreement Dated-27/08/1999, of Flat No. C-402, 4th Floor, in the Building known as "ANANT ASHRAY", Village.- Achole, Nallasopara East, Tal.-Vasai, Dist. Palghar 401209.

So we hereby invite claim or objection that any person having any claim or objection against or into or upon in respect of said Flat howsoever are hereby required to make the same known in writing to our advocate office within 14 days from the date of publication.

Date: 06/02/2021 Mr. D.S. TIWARI
(Advocate High Court)
Shop No. 19, Akanksha Tower,
Near Railway Station, Nallasopara (E).

APOLLO FINVEST (INDIA) LTD.

सीआयएन:एल५१९००एमएच१९८५पीएलसी०३६९९१
नोंदणीकृत कार्यालय: युनिट क्र. ८०३, मोरया ब्ल्यु मून, ८वा मजला, वीरा इंडस्ट्रीयल इस्टेट, न्यु लिंक रोड, लक्ष्मी इंडस्ट्रीयल इस्टेटसमोर, अंधेरी (पश्चिम), मुंबई-४०००५३.

सूचना

सेबी (लिस्टिंग ऑब्लिगेशन्स अँण्ड डिस्क्लोजर रिक्वायरमेंट्स) रेग्युलेशन्स २०१५ च्या नियम २९ व ४७ नुसार येथे सूचना देण्यात येत आहे की, ३१ डिसेंबर, २०२० रोजी संपलेल्या तिमाही व नऊमाहीकरिता कंपनीचे अलेखापरिक्षित वित्तीय निष्कर्ष विचारात घेणे व मान्यता देणे याकरिता शुक्रवार, १२ फेब्रुवारी, २०२१ रोजी कंपनीच्या संचालक मंडळाची सभा होणार आहे.

सदर सूचना कंपनीचे शेअर्स जेथे सूचिबध्द आहेत त्या बीएसई लिमिटेडच्या www.bseindia.com व वेबसाईटवर आणि कंपनीच्या www.apollofinvest.com वेबसाईटवर उपलब्ध आहे.

अपोलो फिनवेस्ट (इंडिया) लिमिटेडकरिता
सही/-
मिखील इन्नानी
ठिकाण: मुंबई व्यवस्थापकीय संचालक
दिनांक: ०५.०२.२०२१ डीआयएन:०२७१०७४९

मोनार्च नेटवर्थ कॅपिटल लिमिटेड

सीआयएन: एल६५९२०एमएच१९९३पीएलसी०७५३९३
नोंदणीकृत कार्यालय: ९०१-९०२, ९वा मजला, अटलांटा सेंटर, उद्योग भवन समोर, सोनावाला रोड, गोरेगाव (पुर्व), मुंबई-४०००६३.
दूरध्वनी:०२२-४३२११६००, फॅक्स:९१-२२-२६८५०२५७
ई-मेल: cs@mnclgroup.com
वेबसाईट: www.mnclgroup.com

सूचना

सेबी (लिस्टिंग ऑब्लिगेशन्स अँण्ड डिस्क्लोजर रिक्वायरमेंट्स) रेग्युलेशन्स २०१५ च्या नियम २९(१)(अ) सहवाचिता ४७(१)(अ) नुसार येथे सूचना देण्यात येत आहे की, खालील प्रकरणे इतर व्यवसायासह ३१ डिसेंबर, २०२० रोजी संपलेल्या तिमाही व नऊमाहीकरिता कंपनीचे एकमेव व एकत्रित अलेखापरिक्षित वित्तीय निष्कर्ष विचारात घेणे व मान्यता देणे याकरिता कंपनीच्या नोंदणीकृत कार्यालयात शुक्रवार, १२ फेब्रुवारी, २०२१ रोजी कंपनीच्या संचालक मंडळाची सभा होणार आहे.

सिक्युरिटीज अँण्ड एक्सचेंज बोर्ड ऑफ इंडिया (प्रोहिबीशन ऑफ इन्सायडर ट्रेडिंग) रेग्युलेशन्स, २०१५ आणि कंपनीचे आतील व्यापार रोखण्याकरिता संचालन सांकेतांकनुसार सुचितप्रमाणे कंपनीचे सर्व संचालक, संबंधित व्यक्ती, प्रवर्तक, कंपनीचे कर्मचारी तसेच त्यांचे परिवार आणि त्यांचे जवळचे नातेवाईक (पुढे विहित व्यक्ती म्हणून संदर्भ) यांच्याकरिता व्यापार खिडकी १ जानेवारी, २०२१ पासून बंद ठेवली जाईल आणि ३१ डिसेंबर, २०२० रोजी तिमाही व नऊमाहीकरिताचे वित्तीय निष्कर्ष घोषणेनंतर ४८ तासांपर्यंत बंद ठेवली जाईल.

सदर सूचना खालील वेबलिंकवर उपलब्ध आहेत:
http://www.mnclgroup.com/investor-relation/investor-relation-announcements.
http://www.bseindia.com/corporates/ann.html?scrip=511551&dur=A

मोनार्च नेटवर्थ कॅपिटल लिमिटेडकरिता
सही/-
ठिकाण : मुंबई रुपाली वर्मा
दिनांक : ०४.०२.२०२१ कंपनी सचिव

इन्टेलिव्हेट कॅपिटल व्हेन्चर्स लिमिटेड

सीआयएन:एल२७२००एमएच१९८२पीएलसी०२८७१५
नोंदणीकृत कार्यालय: ११०४, ए विंग, नमन मिडटाऊन, ११वा मजला, सेनापती बापट मार्ग, प्रभादेवी, मुंबई-४०००१३. कार्यालय:(०२२)२४३९१९८०, २४३९१९३३, फॅक्स:(०२२)२४०३१६९१
ई-मेल:secretarial@intellivatecapital.com, वेबसाईट:www.intellivatecapitalventures.in

सूचना

सेबी (लिस्टिंग ऑब्लिगेशन्स अँण्ड डिस्क्लोजर रिक्वायरमेंट्स) रेग्युलेशन्स २०१५ च्या नियम २९ व ४७ नुसार येथे सूचना देण्यात येत आहे की, ३१ डिसेंबर, २०२० रोजी संपलेल्या तिमाहीकरिता कंपनीचे अलेखापरिक्षित वित्तीय निष्कर्ष विचारात घेणे व मान्यता देणे याकरिता कंपनीच्या नोंदणीकृत कार्यालयात शुक्रवार, १२ फेब्रुवारी, २०२१ रोजी कंपनीच्या संचालक मंडळाची सभा होणार आहे.

सदर सूचना कंपनीचे शेअर्स जेथे सूचिबध्द आहेत त्या बीएसई लिमिटेडच्या (www.bseindia.com) वेबसाईटवर आणि कंपनीच्या www.intellivatecapitalventures.in वेबसाईटवर उपलब्ध आहे.

इन्टेलिव्हेट कॅपिटल व्हेन्चर्स लिमिटेडकरिता
सही/-
लिना मोदी
ठिकाण: मुंबई संचालिका
दिनांक: ०५.०२.२०२१ (डीआयएन:००७९६३८२)

ARROW GREENTECH LIMITED

Regd. Office:1/F Laxmi Industrial Estate, New Link Road, Andheri West), Mumbai 400 053
EMAIL: contact@arrowgreentech.com , TEL: 022 4074 9000,
L21010MH1992PLC069281,

NOTICE

Pursuant to Regulation 29 read with 47 (1) of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 (Listing Regulations), notice is hereby given that a meeting of the Board of Directors of the Company will be held on Thursday 11th February 2021, at the Registered Office of the Company, *inter-alia* to consider and approve Unaudited Financial Results for the quarter ended 31st December 2020.

For Arrow Greentech Limited
Sd/-
Place : Mumbai Poonam Bansal
Date : 05.02.2021 Company Secretary

रिशीरूप लिमिटेड

सीआयएन: एल२५२००एमएच१९८४पीएलसी०३४०९३
नोंदणीकृत कार्यालय: डब्ल्यु ७५(ए) व डब्ल्यु ७६(ए), एमआयडीसी इंडस्ट्रियल एरिया, सातपूर, नाशिक-४२२००७. वेबसाईट: www.rishiroop.in, ई-मेल: investor@rishiroop.com
दूर.:०२२-४०९५२०००, ९१-०२५३-२३५००४२, फॅक्स:९१-२२-२२८७२७९६

३१ डिसेंबर, २०२० रोजी संपलेल्या तिमाही व नऊमाहीकरिता अलेखापरिक्षित वित्तीय निष्कर्षांचा अहवाल

(रू.लाखात)

तपशील	संपलेली तिमाही अलेखापरिक्षित	संपलेली तिमाही अलेखापरिक्षित	संपलेली तिमाही अलेखापरिक्षित	संपलेली नऊमाही अलेखापरिक्षित	संपलेली नऊमाही अलेखापरिक्षित	संपलेले वर्ष लेखापरिक्षित
	३१.१२.२०	३०.०९.२०	३१.१२.१९	३१.१२.२०	३१.१२.१९	३१.०३.२०
कार्यचलनातून एकूण उत्पन्न	२३१२.४१	१४४९.९३	९३३.३३	४४४०.५९	३१३७.८०	४१३१.८१
करपूर्व कालावधीकरिता निव्वळ नफा/(तोटा)	६९१.१०	२६५.१७	१०८.५५	११७१.२०	१६०.६०	(३३९.४७)
करानंतर कालावधीकरिता निव्वळ नफा/(तोटा)	५६४.५५	२१६.६४	१०८.४१	९७६.९१	१६१.९६	(२८४.१२)
कालावधीकरिता एकूण सर्वंकष उत्पन्न (करानंतर कालावधीकरिता एकत्रित नफा व करानंतर इतर सर्वंकष उत्पन्न)	५६६.६१	२१६.७४	१०६.९५	९९३.८८	१६६.९४	(२८३.६२)
कालावधीकरिता निव्वळ एकूण सर्वंकष उत्पन्न/(तोटा)	५६६.६१	२१६.७४	१०६.९५	९९३.८८	१६६.९४	(२८३.६२)
समभाग भांडवल	९७०.१३	९७०.१३	९७०.१३	९७०.१३	९७०.१३	९७०.१३
उत्पन्न प्रतिभाग (रू.१०/- प्रत्येकी)						
१. मूळ	५.८२	२.२३	१.१२	१०.०७	१.६७	(२.९३)
२. सौमिकृत	५.८२	२.२३	१.१२	१०.०७	१.६७	(२.९३)

टिप:

१. वरील एकमेव अलेखापरिक्षित वित्तिय निष्कर्षाचे मंडळाच्या लेखासमितीद्वारे ५ फेब्रुवारी, २०२१ रोजी पुनर्विलोकन करण्यात आले आणि ५ फेब्रुवारी, २०२१ रोजी झालेल्या संचालक मंडळाच्या सभेत नोंद पटावर घेण्यात आले.
२. कंपनीने प्लॉट क्र.५८०७ व ५८०८, जीआयडीसी इंडस्ट्रियल इस्टेट, अंकलेश्वर, गुजरात-३९३००२ येथील धारणाधिकार जमीन व इमारतीचे विक्री, करारनामा, हस्तांतरणासाठी करारनामा केलेला आहे. तद्नुसार ३१ डिसेंबर, २०२० रोजी संपलेल्या तिमाहीत कंपनीने ४ जानेवारी, २०२१ रोजी रक्कम रु.२७६४.८८ लाखांचा व्यवहार करून रक्कम प्राप्त केलेली आहे.
३. संचालक मंडळाने वित्तिय वर्ष २०२०-२१ करिता रु.१०/- प्रत्येकी दर्शनी मुल्याचे (अर्थात ५०%) रु.५ प्रती भागांचा अंतरिम लाभांश घोषित केला आहे.
४. ३१ डिसेंबर, २०२० रोजी संपलेल्या तिमाही व नऊमाहीकरिता एकमेव वित्तीय निष्कर्षांचे कंपनीच्या स्वतंत्र लेखापरिक्षकांनी मर्यादित पुनर्विलोकनकेले आहे. यावर त्यांनी अपात्र अहवाल दिलेला आहे.
५. सेबी (लिस्टिंग ऑब्लिगेशन्स अँण्ड डिस्क्लोजर रिक्वायरमेंट्स) रेग्युलेशन २०१५ च्या नियम ३३ अन्वये स्टॉक एक्सचेंजसह सादर करण्यात आलेली वित्तीय निष्कर्षांचे सविस्तर नमुन्यातील उतारा आहे. वित्तीय निष्कर्षांचे संपूर्ण नमुना स्टॉक एक्सचेंजच्या www.bseindia.com आणि कंपनीच्या www.rishiroop.in वेबसाईटवर उपलब्ध आहे.

संचालक मंडळाच्या आदेशान्वये
रिशीरूप लिमिटेडकरिता
सही/-
आदित्य कपूर
ठिकाण: मुंबई व्यवस्थापकीय संचालक
दिनांक: ०५.०२.२०२१ डीआयएन:००००३०१९

CARYSIL Life style Kitchen Sinks & Built in Appliances

Acrysil Limited

Forbes Asia BEST UNDER A BILLION 2020

GROWTH THROUGH GLOBALIZATION, DIVERSIFICATION & INNOVATION

STANDALONE: 24% (Y-o-Y) (Quarterly) Revenue; 48% (Y-o-Y) (Quarterly) EBIDTA; 87% (Y-o-Y) (Quarterly) PAT
CONSOLIDATED: 17% (Y-o-Y) (Quarterly) Revenue; 46% (Y-o-Y) (Quarterly) EBIDTA; 78% (Y-o-Y) (Quarterly) PAT

३१ डिसेंबर, २०२० रोजी संपलेल्या तिमाही व नऊमाहीकरिता अलेखापरीक्षित (एकमेव व एकत्रित) वित्तीय निष्कर्षांचा अहवाल

(रु. लाख, ईपीएस व्यतिरिक्त)

अ.क्र.	तपशिल	एकमेव संपलेली तिमाही ३१.१२.२० अलेखापरिक्षीत	एकमेव संपलेली तिमाही ३०.०९.२० अलेखापरिक्षीत	एकमेव संपलेली तिमाही ३१.१२.१९ अलेखापरिक्षीत	एकमेव संपलेली नऊमाही ३१.१२.२० अलेखापरिक्षीत	एकमेव संपलेली नऊमाही ३१.१२.१९ अलेखापरिक्षीत	एकमेव संपलेले वर्ष ३१.०३.२० लेखापरिक्षीत	एकत्रित संपलेली तिमाही ३१.१२.२० अलेखापरिक्षीत	एकत्रित संपलेली तिमाही ३०.०९.२० अलेखापरिक्षीत	एकत्रित संपलेली तिमाही ३१.१२.१९ अलेखापरिक्षीत	एकत्रित संपलेली नऊमाही ३१.१२.२० अलेखापरिक्षीत	एकत्रित संपलेली नऊमाही ३१.१२.१९ अलेखापरिक्षीत	एकत्रित संपलेले वर्ष ३१.०३.२० लेखापरिक्षीत
१.	कार्यचलनातून एकूण उत्पन्न	७०८२.८२	६३११.०९	५७२६.३३	१७११६.२९	१६७७१.६३	२१९३५.९७	८७८३.४०	७७४६.९८	७४९२.५६	२१२३१.४६	२१४९४.१५	२८०९५.९९
२	कालावधीकरिता निव्वळ नफा/(तोटा) (कर, अपवादात्मक आणि/किंवा विशेष साधारण बाबपूर्व)	११३९.३३	९१७.७४	६२१.१३	२५९३.१३	१५५२.२९	१८२१.००	१५७७.७४	१२७५.६०	९११.६९	३४५४.७२	२४६२.८६	३०४८.१८
३	करपूर्व कालावधीकरिता निव्वळ नफा/(तोटा) (अपवादात्मक आणि/किंवा विशेष साधारण बाबनंतर)	११३९.३३	९१७.७४	६२१.१३	२५९३.१३	१५५२.२९	१८२१.००	१५७७.७४	१२७५.६०	९११.६९	३४५४.७२	२४६२.८६	३०४८.१८
४	करानंतर कालावधीकरिता निव्वळ नफा/(तोटा) (अपवादात्मक आणि/किंवा विशेष साधारण बाबनंतर)	८४३.०९	६५०.८१	४५०.४६	१८९५.३१	११०९.२६	१२७९.१३	१२१७.५०	९४६.२१	६८४.२९	२६१९.९७	१८३६.००	२२८६.२०
५	कालावधीकरिता एकूण सर्वंकष उत्पन्न (कालावधीकरिता एकत्रित नफा/(तोटा)(करानंतर) आणि इतर सर्वंकष उत्पन्न (करानंतर))	८३७.३४	६४५.०८	४५२.४७	१८७८.०९	१११५.२८	१२५६.१८	११९७.६९	९३२.८४	५९५.३६	२५७६.६०	१७९०.७२	२१७५.८२
६	समभाग भांडवल (दर्शनी मुल्य रु.२/- प्रति)	५३३.९०	५३३.९०	५३३.९०	५३३.९०	५३३.९०	५३३.९०	५३३.९०	५३३.९०	५३३.९०	५३३.९०	५३३.९०	५३३.९०
७	इतर समभाग						१२४९९.७१						१५२४७.२५
८	उत्पन्न प्रतिभाग (दर्शनी मुल्य रू.२/- प्रत्येकी) (वार्षिकीकरण नाही)												
	१. मूळ	३.१६	२.४४	१.७२	७.१०	४.२३	४.८६	४.५३	३.५२	२.६०	९.७७	६.९३	८.३८
	२. सौमिकृत	३.१६	२.४४	१.७२	७.१०	४.२३	४.८६	४.५३	३.५२	२.६०	९.७७	६.९३	८.३८

टिप :

१) वरील वित्तीय निष्कर्षाचे लेखासमितीद्वारे पुनर्विलोकन व शिफारस करण्यात आले आणि ५ फेब्रुवारी, २०२१ रोजी झालेल्या संचालक मंडळाच्या सभेत मान्य करण्यात आले. उपरोक्त निष्कर्षाचे कंपनीच्या वैधानिक लेखापरिक्षकांनी मर्यादित पुनर्विलोकन केले आहे.
२) सेबी (लिस्टिंग ऑब्लिगेशन्स अँण्ड डिस्क्लोजर रिक्वायरमेंट्स) रेग्युलेशन २०१५ च्या नियम ३३ अन्वये स्टॉक एक्सचेंजसह सादर करण्यात आलेली ३१ डिसेंबर, २०२० रोजी संपलेल्या तिमाही व नऊमाहीकरिता वित्तीय निष्कर्षाचे सविस्तर नमुन्यातील उतारा आहे. त्रैमासिक एकमेव व एकत्रित वित्तीय निष्कर्षाचे संपूर्ण नमुना स्टॉक एक्सचेंजच्या www.bseindia.com व www.nseindia.com वेबसाईटवर आणि कंपनीच्या www.acrysilcorporateinfo.com वेबसाईटवर उपलब्ध आहे.
३) वरील अहवाल हे कंपनी कायदा २०१३ चे कलम १३३ आणि इतर लागू मर्यादित मान्यताप्राप्त लेखा योजनेनुसार विहित कंपनी (भारतीय लेखाप्रमाण) अधिनियम, २०१५ (इंडएएस) नुसार तयार केले आहेत.

Acrysil Limited
नोंदणीकृत कार्यालय:
बी-३०७, सिटी पॉईंट, जे.बी. नगर, अंधेरी-कुर्ला रोड, अंधेरी (पुर्व), मुंबई-४०००५९. दुर.:०२२-४०१५७८१७/१८/१९, ई-मेल:cs.al@acrysil.com, वेबसाईट:www.acrysil.com, www.acrysilcorporateinfo.com, सीआयएन: एल२६९१४एमएच१९८७पीएलसी०४२२८३

मंडळाच्या आदेशान्वये
ॲक्रिसील लिमिटेडकरिता
ठिकाण: भावनगर चिराग ए. पारेख
दिनांक: ०५.०२.२०२१ अध्यक्ष व व्यवस्थापकीय संचालक

Amazon, Others Pledge About ₹500 cr to 'Cover' Gig Workers

Proposed fund under ESIC to provide health insurance to 1 m workers

Yogima.Sharma
@timesgroup.com

New Delhi: More than a dozen companies including Amazon, Flipkart, Swiggy, Ola and Uber have committed about ₹500 crore to the government's proposed social security fund that will provide health insurance to one million gig workers, a top official told **ET**.

The labour ministry has finalised the scheme for gig workers under the Employees' State Insurance Corporation, which will be announced alongside the rollout of the Social Security Code.

The initial commitments by the ecommerce platforms and ride aggregators are based on the options given to them under the Code, the official said.

"The above contribution is based on 1% of revenue of the platforms," the official said.

The Code had provided for contribution of 1-2% of revenue of the platform or 5% of the wages paid to the worker. However, it has been decided to peg it at 1% of revenue.

This will be topped up by a minuscule monthly contribution of up to Rs 100 from the gig worker.

The government will, however, not make any monetary contribution.

Benefits for Gig Workers

Labour ministry finalises scheme for gig workers under the Employees' State Insurance Corporation

Health, other benefits under ESIC will be provided

Platforms, workers to contribute to the social security fund

Over a dozen firms on board to cover one million workers



Platforms to contribute ₹500 cr in first year

Workers' contribution up to ₹100 a month

The platforms will be required to make an annual contribution by June 30 each year on a self-assessment basis.

Companies will need to submit a form specifying the number of gig workers associated with them at the start of each financial year along with the preceding year's annual turnover.

On their part, the gig workers will have to update particulars such as current address, job, period of engagement with the gig firm, skills, and mobile number on the portal specified by the government to avail of such benefits.

Gig workers covered under the scheme will be eligible for medical, maternity, disability and other benefits and would have access to ESIC hospitals. The labour ministry is ready with the rules under the four labour Codes, which will be notified soon, the official said.

Gig workers are a portable workforce that work with e-commerce platforms, taxi aggregators and food delivery firms, among others. However, the white-collar gig workforce, often referred to as freelance consultants, will not be part of the beneficiaries in the first year as the scheme.

Edelweiss Wealth Mgmt Eyes ₹1kcr from Equity-focused AIF

Mumbai: Edelweiss Wealth Management is targeting to raise ₹1,000 crore from domestic investors for its maiden equity-focused alternate investment fund (AIF), according to persons in the know.

The fundraising, which comes amid a strong rally in the markets that has led to concerns overvaluation, will take about 6-9 months, and the company will target HNIs, family offices and institutional investors for investment commitments, the sources said.

When contacted, Edelweiss declined to comment.

The sources in the know said the company is targeting to raise over ₹1,000 crore in the Edelweiss Dynamic Growth Equity Fund and raise more money based on the performance. Over the next few months, it plans to go overseas for widening its asset under management pool through the AIF. — PTI

Centre Likely to Incentivise Stake Sale in State PSUs

Funds equivalent to disinvestment receipts of states may be offered

Deepshikha.Sikarwar
@timesgroup.com

ANIRBAN BORA

New Delhi: The Centre could offer funds equivalent to disinvestment receipts raised by states to incentivise them to pursue stake sales in state-owned enterprises.

"We are working out the incentives… We could match up the disinvestment receipts raised by them," a senior government official told **ET**.

The official said the incentives would be finalised soon after the passage of the budget by Parliament. Finance minister Nirmala Sitharaman had said in her budget speech the Centre would incentivise disinvestment by states. "To similarly incentivise states to take to disinvestment of their public sector companies, we will work out an incentive package of central funds for states," she had said on February 1.

The Centre's approach of linking reforms by states to additional borrowing has yielded good results. As many as 12 states have implemented ease of doing business reforms to avail of the additional borrowing window and the Centre's view is that this could work with disinvestment as well.

The government has identified privatisation as a key focus area, with the new public sector policy setting out four areas as strategic where a bare minimum of central public sector enterprises will be maintained and the rest privatised. In the remaining sectors, all CPSEs will be privatised.

The Centre is keen that the states also pursue the policy framework to free up resources that could be put to more productive uses, including building infrastructure.

Previous Finance Commissions had flagged the need for states to disinvest stake in their public sector enterprises and to set up a taskforce to chalk out a framework in this regard.

There are over 1,100 state PSUs, a large number of which are non-functional enterprises that have investments locked in and land assets at their disposal.

'Untrustworthy States'

►► From Page 1

The high-profile Dholera solar park project is part of the Dholera Special Investment Region (DSIR), approved by chief minister Vijay Rupani and part of the Centre's flagship Delhi-Mumbai Industrial Corridor.

O2 said most international investors had stopped bidding for solar and wind projects because of the poor financial health of state utilities. "Gujarat had been one exception, where investors had reposed faith in the state government," O2 said in its February 1 note, which **ET** has seen. "But with this backout, Gujarat too joins the league of untrustworthy states."

The letter pointed out that bid winners have "significant" overseas investment — ReNew Power (funding from Goldman Sachs, Canada Pension Plan Investment Board, Japan's JERA, Abu Dhabi Investment Authority, Global Environment Facility); O2 Power (Temasek and Swedish private equity group EQT); Vena Energy (Global Infrastructure Partners); Tata Power (Petronas and other investors in its renewable infrastructure investment trust).

"This backing out will severely dent not just Gujarat's, but the whole country's investment image on the global platform," O2 said. "India's overall environment commitment through renewable energy will be impacted by this move."

A PMO spokesperson didn't respond to queries. People aware of the matter said the PMO has begun consultations with the renewable energy ministry on the matter.

UNHAPPY PRECEDENCE

This follows the Andhra Pradesh government's cancellation of enforceable power purchase agreements coming under scrutiny at the Andhra Pradesh High Court and the Supreme Court. The move has already eroded investor confidence in India's renewable story, analysts said.

Temasek is the investment arm of the government of Singapore and a key economic partner for India. The firm has already invested $11 billion in India and, together with Singapore's sovereign wealth fund GIC, is the largest FDI contributor.

In 2019, Temasek and EQT, which is backed by the Wallenbergs — a family with stakes in AstraZeneca, Electrolux, SAAB and Ericsson, among others — launched O2 Power as a 50:50 joint venture.

"This not only dents investor confidence, but also sets a bad precedent to cancel out projects that have already been bid out," said Shekhar Dutt, director general of the Solar Power Developers Association. "If investors' confidence goes, then banks and financial institutions' loans become difficult."

O2 said most international investors had stopped bidding for solar and wind projects because of the poor financial health of state utilities

The latest development is similar to another row, said the CEO of one of the companies. "Just a few months ago, ADIA had to seek the PMO's help over sanctity of contracts in India during the takeover drama over Mumbai airport," he said. "It just adds to the reputational risks of the country."

A DIFFICULT PROJECT

It took Gujarat more than two years to conclude the 1 GW Dholera Solar Park tender in 2020. Dholera's terrain makes it difficult to construct sustainable foundations, adding to costs. The site remains flooded for about nine months in a year, said solar developers.

However, it benefited from the strategic importance of the corridor and a push from the PMO to showcase the successful reuse of waste instead of arable land.